Articles tagged with Glioblastomas
Researchers at Ohio State University found that blocking an enzyme used by glioblastoma cells to store fats may be a new way to treat the deadly disease. This approach could also apply to other types of cancers that use lipid droplets for energy.
A new PET radiotracer has been proven safe and effective in imaging malignant brain tumors with high sensitivity. The radiotracer targets αvβ3 integrin, which is overexpressed in glioblastomas, allowing for superior visualization of tumors.
Researchers have developed a novel immunotherapy using genetically modified natural killer cells to target and kill cancer cells in glioblastoma multiforme, a highly aggressive brain tumor. The treatment approach has shown high efficiency and is considered safer than other cell-based therapies.
Researchers developed a promising immunotherapy treatment for glioblastoma using CD133-targetting CAR-T therapy, which showed enhanced activity in preclinical models of human glioblastoma. The therapy was considered successful due to reduced tumor burden and improved survival rates.
Researchers discovered that lumefantrine, an FDA-approved anti-malarial drug, can inhibit the genetic element Fli-1 controlling resistance to radiation and chemotherapy in glioblastoma multiforme. Lumefantrine also suppresses tumor cell growth and inhibits key processes regulating cancer invasion and spread.
A new predictor for brain cancer patients' life expectancy has been developed using a genome-wide pattern of DNA copy numbers. The pattern identifies patients who survive for a median of three years, three times longer than those without it.
A new platform has been developed to deliver molecules that target specific genes within cells, showing promise in treating glioblastoma brain cancer. The system uses a modified form of diphtheria toxin to escape the cell's endosome and deliver therapeutic vehicles.
A combination of immunotherapy agents encourages immune cells to consume tumors and alert others to attack, boosting survival for glioblastoma patients. The therapy, tested in a mouse model, successfully shrank tumors and extended life, with 55% of animals surviving over the course of the study.
Researchers discovered that PHIP protein resides at the leading edge of GBM cells, enabling other adhesion proteins to deepen the grip of cancerous cells on healthy brain tissue. Suppressing PHIP helped inactivate proteins that form the machinery for tumor cell movement, driving aggressive behavior.
Researchers developed a new CAR T cell therapy using chlorotoxin, a component of scorpion venom, to target glioblastoma cells. The therapy showed promise in killing tumor cells while ignoring healthy tissue.
A new Penn study found that imaging techniques, such as MRI, may help identify which glioblastoma patients are best candidates for liquid biopsies. The research showed a correlation between the blood-brain barrier and macrophage density with circulating DNA levels, suggesting the potential for personalized treatment decisions.
New research from Penn Medicine suggests blocking the Wnt pathway can make chemotherapy more effective against glioblastoma. The study found that targeting stromal cells, which act like stem cells and promote tumor growth, may be an effective way to overcome treatment resistance.
A retrospective study found that patients who underwent regular surveillance imaging after surgery had similar median survival rates to those who only returned when they felt symptoms of recurrence. The results suggest less frequent imaging could improve patient convenience and reduce costs.
A retrospective study by researchers at UC San Francisco found that removing the non-contrast-enhancing tumor increases survival for adults with glioblastoma. Patients with IDH-mutant tumors who underwent resections of both contrast-enhancing and non-contrast-enhancing tumor had a significantly longer average survival time, around 37.3...
UC San Diego researchers identified αvβ5 integrin as the key contributor to Zika virus' ability to infect brain cells. Blocking this integrin with antibodies or small molecule inhibitors effectively prevents Zika virus from infecting both normal brain stem cells and cancer stem cells.
The Akay Lab has developed a new microfluidic brain cancer chip that can simultaneously administer multiple drugs and assess their response to glioblastoma cells. The device enables fast drug combination testing in as little as two weeks, potentially improving patient survival rates.
A new study found that reinforcing the meningeal lymphatic network increases tumor antigen traffic from the meninges to lymph nodes, triggering activation of immune cells against the tumor. This approach combines with existing immunotherapy for effective glioblastoma eradication.
Scientists have found a novel method to combat glioblastoma, a deadly brain tumor, by introducing VEGF-C into the cerebrospinal fluid of mice. This approach significantly extended survival rates when combined with immune system checkpoint inhibitors, offering new hope for treatment options.
Researchers at Mount Sinai are exploring new treatments for brain tumors, including magnetic hyperthermia therapy and studies on glioma dormancy and tumor microenvironment. The grant funding will support five-year projects focused on improving patient outcomes through innovative therapies.
Researchers have developed glioblastoma organoids from patient tissue, allowing them to rapidly test personalized treatment strategies. The models retain features from the primary tumor and can be used to explore ways to attack it.
A study by researchers at the University of Texas M.D. Anderson Cancer Center identified a subset of immune macrophages that resist treatment with anti-PD-1 checkpoint blockade in glioblastoma patients. The team found that these CD73-expressing macrophages were associated with decreased survival, and that targeting them with combinatio...
Researchers at Massachusetts General Hospital and the University of Florida have identified a promising strategy to make glioblastoma susceptible to immune checkpoint inhibitors. The approach targets chemokine receptors that allow myeloid-derived suppressor cells to infiltrate tumors, leading to immunosuppression and treatment resistance.
A study found that glioblastoma patients with a history of Human cytomegalovirus (HCMV) infection had a significantly shorter survival rate, highlighting the potential use of HCMV testing to predict treatment outcomes. The presence of HCMV antibodies was linked to a four-month reduction in life expectancy.
Researchers found that MALT1 levels correlate with patient survival in brain cancer, and blocking the gene with MALT1 inhibitors causes glioblastoma stem cells to undergo cellular suicide. This discovery points to the potential of further exploring MALT1 inhibitors as a treatment for glioblastoma.
The Ivy Brain Tumor Center is collaborating with SonALAsense to develop and test sonodynamic therapy, a promising new treatment for recurrent glioblastoma. The Phase 0/2 clinical trial will assess the safety and efficacy of this non-invasive therapy in patients with glioblastoma.
Researchers discovered that SNAP, a nitric oxide donor, overcomes TMZ resistance in glioblastoma multiforme (GBM) cells by reducing MGMT protein stability. This finding offers a potential strategy to improve treatment outcomes for patients with GBM.
Researchers at Karolinska Institutet have identified 10 novel glioblastoma-specific endothelial cell transcripts that could represent potential tumour-targets for therapy. The study uses a new method to process human brain tissue data and identifies disease-related changes in cells lining tumour blood vessels.
Researchers developed a blood test that measures cell-free DNA (cfDNA) to predict prognosis in glioblastoma patients. The test correlates with progression-free survival and detects genetic mutations not found in solid tissue biopsies, offering a complementary view of the tumor's molecular profile.
A compound has been identified as effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs), a major challenge in treating this devastating cancer. The research also showed that the compound is non-toxic to normal cells, raising hopes for developing drugs with low toxicity.
University of Minnesota Medical School researchers have made a breakthrough in combating glioblastoma, the most common form of adult brain cancer. By combining ultrasound with engineered glass particles, they were able to create a 'Goldilocks' balance that awakens the body's immune response and boosts the effectiveness of immunotherapy.
Researchers at the Spanish National Research Council (CSIC) have found that glioblastoma hijacks pericytes to promote tumor progression and evade the immune system. By targeting chaperone-mediated autophagy, they may develop a new therapeutic approach to treat this aggressive brain cancer.
Researchers at the University of Georgia have discovered a new use for an existing insulin compound to treat glioblastoma, a fast-growing and often fatal form of brain cancer. The study found that surfen-treated cells were blocked from tumor growth and the spread of tumor cells in the brain.
Scientists at USC and UC San Diego have discovered a potential novel target for treating glioblastoma, the deadliest form of brain cancer. They found that targeting the circadian clock in tumor stem cells can disrupt the growth and development of the tumor, leading to its death.
Researchers at Texas A&M University have found that the AH receptor can actually block invasion of glioblastoma cells, rather than promoting it. Adding certain ligands to the receptor has been shown to inhibit cell invasion and provide additional protection to the brain.
Researchers at Cleveland Clinic have identified FGF2 as a novel druggable target for glioblastoma, the most common primary malignant brain tumor. The study reveals that FGF2 is an intermediary in a multi-step pro-cancer signaling loop, suggesting that targeting it may halt the growth and spread of glioblastoma.
A study published in Acta Neuropathologica Communications found that interregional differences in the somatic genetic landscape of glioblastoma affect prognosis. The research analyzed Japanese patients with IDH-wildtype GBM and discovered a biomarker, triple CNA, associated with survival duration.
Researchers at the University of Sussex have identified novel biomarkers in bodily fluids that could signal the presence of glioblastoma. These biomarkers are associated with extracellular vesicles and may enable a simpler way to test for the tumor, rather than a biopsy.
A two-step gene therapy treatment has shown promise in treating recurrent glioblastoma by boosting IL-12 production and enhancing antitumor immune cell infiltration. The treatment has also been found to be safe, with serious side effects easily reversible after discontinuing treatment.
A clinical trial found that an oral activator, veledimex, controlled the transcription of human interleukin-12, reducing toxicity while preserving anti-tumor effects. Patients with recurrent glioblastoma had improved overall survival rates, with some experiencing up to 17.8 months of survival.
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
A Phase 0 clinical trial shows ribociclib effectively targets glioblastoma cells and breaks the blood-brain barrier, offering a new treatment hope. The study identifies a potential mechanism of drug resistance, paving the way for a combined-drug regimen to overcome resistance.
A study identified Glycerol-3-phosphate dehydrogenase 1 (GPD1) as a molecular marker specific to dormant glioma stem cells. GPD1-producing cells are resistant to chemotherapy and radiation, and their activation leads to tumor relapse.
Researchers found that inhibiting ID1 slows tumour progression in glioblastoma, breast and melanoma. Targeting the protein with medication may present a promising strategy for patients.
A recent study found that only 5.5% of glioblastoma patients survive five years after diagnosis, highlighting the need for more aggressive treatments to improve long-term survival. The research analyzed 48,652 cases and identified factors associated with five-year survival, including age, race, gender, and treatment with radiotherapy.
Research at MD Anderson Cancer Center discovers a symbiotic circuit between PTEN-deficient glioblastoma cells and macrophages, which creates a mutually supportive relationship. Inhibiting LOX, a novel attractor of macrophages, shrinks tumors and blocks macrophage infiltration.
Researchers paired a calorie-restricted ketogenic diet with a tumor-inhibiting antibiotic to destroy cancer stem cells and mesenchymal cells in glioblastoma, a fast-moving brain cancer. The combination killed tumor cells while reversing disease symptoms and improving mouse survival.
Researchers at IRB Barcelona discovered that the antibody mAb806 can be used to treat many types of tumors with EGFR mutations, not just a specific one. The study also found that even non-mutated EGFR can be treated to make it susceptible to mAb806 therapy.
Researchers from FEFU and international partners discover potential targets for glioblastoma multiforme treatment by studying proteins in the WNT signaling pathway. The findings could lead to improved antitumor therapy outcome through suppression of cancer stem cells, accelerating tumor growth rate.
Researchers discovered multiple potential targets for glioblastoma by systematically profiling patient-derived brain tumour cells. They found that adult glioblastoma cells rely on genes important for brain development in infancy, highlighting the need for new research to understand the developing human brain.
Scientists identified a molecular driver of glioblastoma, a highly aggressive and treatment-resistant brain cancer, by analyzing cell-by-cell genetic data. Researchers found that reprogramming primitive oligodendrocyte progenitors into stem-like cells plays a key role in glioma initiation and progression.
A new experimental glioblastoma vaccine developed by Jefferson and Imvax has shown promising results in a phase Ib clinical trial. The treatment was found to slow tumor recurrence and prolong patient survival in patients with newly diagnosed glioblastoma multiforme.
Researchers identified three key genetic drivers of glioblastoma development, including the activation of telomerase. Early tumors exhibit concurrent genetic alterations, but recurrent tumors display distinct mutation patterns. This study highlights the need for new treatments to effectively target resistant subclones.
A team of researchers discovered a way to make glioblastoma brain tumors more sensitive to radiation by blocking the activity of a specific protein, PTEN. This breakthrough could lead to improved treatment prospects for patients with this aggressive form of brain cancer.
Researchers at the University of Bonn have reported significant progress in treating aggressive brain tumors like glioblastoma. Combination chemotherapy with CCNU and temozolomide significantly prolongs patients' survival time, with a notable benefit for those with methylated MGMT promoter.
Research reveals that patients with specific MAPK mutations are more likely to respond to immunotherapy drugs in glioblastoma. The study also found that tumors with PTEN mutations were less responsive to treatment, suggesting new targets for treatment development.
A multidisciplinary team of researchers has developed a human induced pluripotent stem cell (IPSC) derived 3D organoid model for drug testing. The system demonstrated anti-tumor efficacy with doxorubicin and predicted clinical response to temozolomide, offering a more personalized approach to treating glioblastoma.
A study by MGH researchers reveals that brain tumors use existing blood vessels to resist anti-angiogenic drugs, leading to compression and stimulation of angiogenesis. The study suggests targeting vessel co-option before using anti-angiogenic drugs could be an effective strategy for glioblastoma treatment.
A new method of using multiple microRNAs to weaken cancer cells has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The treatment strategy weakens tumor cells but does not directly kill them, making it an advantage for further treatment.
Researchers at MD Anderson Cancer Center have discovered a link between FGL2 protein and glioblastoma progression. FGL2, known for suppressing the immune system, is highly expressed in GBM and can be eliminated by knocking it out, eliminating tumor progression in mice with intact immune systems.
A recent study has found that standard treatment for glioblastoma is more effective in women than men, with tumor growth velocity showing a steady decline after treatment. The researchers identified distinct molecular signatures of the disease in men and women, which could lead to sex-specific treatment strategies.